Social Media is omnipresent and harnessing its power should be high on lists of healthcare providers (HCPs). How do they get their message out to reach the right people at the right time and how do they distinguish themselves from their competitors? Here are 12 predictions and factors for 2022.
How early stage can help set you up for big stage.
Life sciences companies a likely targets of these kinds of attacks.
Webinar Date/Time: Mon, Dec 5, 2022 2:00 PM EST
Leveraging RWD can lessen the strain normally put on investigators and sites.
How technology can maximize use of manufacturer copay and patient assistance programs.
Five emerging themes likely to impact pharma in the new year.
Dr. Chris Smyth, president of ICON Biotech, discusses emerging trends in the biotech space.
Oral solid dose formulations (OSD) continue to lead the market as a preferred dosage form. To gain better insight into drug dose delivery technology trends, Laura Child spoke to leaders from five top contract development and manufacturing organizations to find out what is on the horizon for patient-centric drug delivery.
New regulations set stage for updated ESG considerations.
Insight that can help smaller biotech companies prepare for commercialization in the world of big pharma.
Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
On the back of COVID-19, pharma has an opportunity to radically rethink a long-held reluctance to build end-customer relationships into their core business models, writes Simon Bates and Valerie Phillips.
Assessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
Commercializing an orphan drug can be challenging, however, using a framework and a checklist that incorporates the right elements can prove beneficial.
New technology is allowing teams to analyze data at faster rates and make decisions much sooner than they previously could.
The industry holds the key to true change to the drug access landscape.
With the increasing adoption of COAs, the importance of standardization across training, collection, and implementation to ensure high quality and consistent data collection has become apparent in recent decades.
Comprehensive dosage monitoring of topical treatments for mild to moderate psoriasis.
COVID-19 pandemic sets new standards for life sciences industry.
Webinar Date/Time: Thu, Mar 28, 2024 2:00 PM EDT
Amid attention on coronavirus, efforts to address the burden of non-communicable diseases are at a critical juncture.
Substance use disorder is a complex condition that demands innovative solutions, one of which that has shown promise is the use of long-acting injectables.
Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
A survey of 18 biopharmas, measuring their scope and implementation across key health equity dimensions and activities, uncovers useful context as companies seek better alignment of these goals with overall strategy.